Center for Mucosal Immunobiology and Rheumatic Disease Pathogenesis

科罗拉多大学的一大批研究人员正致力于表征 起源和因果机制，驱动风湿性和自身免疫性疾病的起始和临床前阶段 疾病这些努力的最重要成果之一是在人口中的示范- 粘膜部位的生态失调和慢性炎症可以促进最初的局部炎症， 对自身抗原的疾病特异性耐受性丧失的发展。最终，这一过程导致系统性 自身免疫和疾病的发展，包括类风湿性关节炎（RA）和脊椎关节炎 （西班牙）。在这一概念的基础上，考虑到独特的高危人群和广泛的方案基础设施， P30风湿病研究资源中心（RDRRC），名称为“粘液免疫生物学中心 与风湿病发病机理的关系。该中心包括一个行政核心， 人口和数据科学核心，以及粘液免疫生物学核心。该中心专门设计 促进人类疾病发病机制的研究，包括广泛的粘膜和全身性的 免疫技术，以及开发新的方法，研究这些综合机制， 在疾病的临床前阶段和临床活动阶段招募个体队列。的 中心包括43名内部和外部成员，他们的相关年度直接成本总计为7700万美元 赠款资金。除了提供对储存的生物标本和正在进行的人群数据的访问外， 研究，该中心将提供咨询和会员折扣机制的所有关键方面， 队列发展、流行病学评估、数据管理和数据分析。此外，中心 将为成员提供专注于微生物组和微生物：细胞分析的技术 相互作用以及提供信息的粘膜和外周免疫生物标志物。该中心将建立在 院长最近投资8000万美元，资助该中心将与之互动的其他四个相关项目。 博士医学和免疫学教授Michael Holers将担任中心主任， 医学副教授库恩将担任副主任。两者都将与咨询 和执行委员会，在后者将加入核心董事和联席董事与域 专业知识作为该中心使命的一个关键组成部分，试点和可行性赠款计划将 得到了大量的机构支持。额外的丰富计划活动将包括一个研讨会 系列、技术评估系列和年度研讨会。一个主要的重点将是早期的职业生涯 通过加强核心访问以及赠款审查和学者计划来发展研究者。 社交媒体、网络外联和通讯将提供全面的沟通。最后 患者影响计划将用于评估和增强新型生物标志物的翻译， 将RDRRC的治疗相关发现转化为直接的患者护理，以改善结局。

A substantial cadre of investigators at the University of Colorado are focused on characterizing the molecular origins and causal mechanisms that drive the initiation and preclinical phases of rheumatic and autoimmune diseases. One of the most important outcomes of those efforts has been the demonstration in populations at- risk for future disease that dysbiosis and chronic inflammation at mucosal sites can promote the initial local development of disease-specific loss of tolerance to autoantigens. Ultimately, this process leads to systemic autoimmunity and the development of diseases including rheumatoid arthritis (RA) and spondyloarthroarthritis (SpA). Building on that concept with unique at-risk populations and an extensive programmatic infrastructure, a P30 Rheumatic Disease Research Resource Center (RDRRC) entitled “Center for Mucosal Immunobiology and Rheumatic Disease Pathogenesis” is proposed. Included in the Center are an Administrative Core, a Population and Data Sciences Core, and a Mucosal Immunobiology Core. This Center is specifically designed to facilitate studies of human disease pathogenesis that incorporate the broad range of mucosal and systemic immunologic techniques, as well as develop new approaches, to study these integrated mechanisms in already recruited cohorts of individuals throughout the preclinical and then clinically active phases of disease. The Center includes 43 internal and external members who have in aggregate $77M in related annual direct cost grant funding. In addition to providing access to stored biospecimens and data from ongoing population studies, the Center will provide consultative and member discount mechanisms for all of the critical aspects of cohort development, epidemiologic assessment, data management and data analyses. In addition, the Center will provide members access to technologies that focus on analyses of the microbiome and microbial:cell interactions, as well as informative mucosal and peripheral immune biomarkers. The Center will build on a recent $80M investment from the Dean to fund four other relevant programs with which this Center will interact. Dr. Michael Holers, Professor of Medicine and Immunology, will serve as the Center Director, and Dr. Kristi Kuhn, Associate Professor of Medicine, will serve as the Associate Director. Both will interact with Advisory and Executive Committees, and in the latter will be joined by Core Directors and Co-Directors with domain expertise. As a key component of the mission of the Center, a Pilot & Feasibility Grants Program will be developed with substantial institutional support. Additional Enrichment Program activities will include a seminar series, technology assessment series, and an annual symposium. A major focus will be on early career investigator development through enhanced Core access as well as Grants Review and a Scholars Programs. Social media, web-based outreach and newsletters will provide comprehensive communication. Finally, a Patient Impact Program will be utilized for the assessment and enhanced translation of novel biomarkers and therapeutically relevant RDRRC discoveries into direct patient care with the goal to improve outcomes.